Abbvie INC. (ABBV)
NYSE · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ABBV in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ABBV and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ABBV at a glance
Key statistics
$510.84B
Market capitalization
- Previous close
- $289.08
- Open
- $287.71
- Day range
- $282.18 – $288.88
- Volume
- 2.02M
- Average volume (30 sessions)
- 4.79M
- Shares outstanding
- 1.77B
- Price / earnings
- 81.2
- Earnings per share
- $3.56
- Price / sales
- 7.9
- Dividend yield
- 2.34%
- Beta (1 year, vs SPY)
- -0.13
Where the price sits in its year
52-week range
92% of the range
- Below the 52-week high
- -2.7%
- Above the 52-week low
- +48.6%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $272.03+6.3%
- 50-day average
- $264.01+9.5%
- 200-day average
- $234.52+23.3%
In the band above 70 that convention calls overbought. Strong trends can stay there for weeks.
+5.4%
1 week
+9.3%
1 month
+14.1%
3 months
+26.5%
Year to date
+25.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ABBV
ABBV on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ABBV.
See the plans →
Every planScreen names like ABBV
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ABBV
Put ABBV on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ABBV
See whether there is an open premium alert on ABBV, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ABBV headlines
SEC Form 4, most recent first
Insider filings
RAPP EDWARD J
+129
Director · Grant or award
$33.75K · Sep 30, 2026
Quaggin Susan E
+59
Director · Grant or award
$15.43K · Sep 30, 2026
Donoghoe Nicholas
+32.7K
EVP, CHIEF BUS/STRAT OFFICER · Option exercise
$2.58M · Aug 14, 2026
Donoghoe Nicholas
−32.7K
EVP, CHIEF BUS/STRAT OFFICER · Option exercise
· Aug 14, 2026
Donoghoe Nicholas
−32.7K
EVP, CHIEF BUS/STRAT OFFICER · Open-market sale
$8.18M · Aug 14, 2026
RAPP EDWARD J
+134
Director · Grant or award
$33.72K · Jun 30, 2026
Quaggin Susan E
+62
Director · Grant or award
$15.60K · Jun 30, 2026
FREYMAN THOMAS C
+1.1K
Director · Grant or award
· May 8, 2026
About Abbvie INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- North Chicago, IL
- Employees
- 57,000
- Listed since
- Dec 10, 2012
- Website
- abbvie.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.